XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY /DEFICIT - USD ($)
$ in Thousands
Total
Previously Reported
Revision of Prior Period, Adjustment
Common Stock Outstanding
Common Stock Outstanding
Previously Reported
Common Stock Outstanding
Revision of Prior Period, Adjustment
Additional Paid-in Capital
Additional Paid-in Capital
Previously Reported
Additional Paid-in Capital
Revision of Prior Period, Adjustment
Accumulated Deficit
Accumulated Deficit
Previously Reported
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income
Previously Reported
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022       10,422,051 2,382,358 8,039,693              
Beginning balance at Dec. 31, 2022 $ (428,722) $ (428,722) $ 0 $ 1 $ 0 $ 1 $ 24,782 $ 24,783 $ (1) $ (456,245) $ (456,245) $ 2,740 $ 2,740
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation expense 3,505           3,505            
RSA vesting (in shares)       2,535,825                  
Repurchase of equity instruments (in shares)       (771,141)                  
Repurchase of equity instruments (7,650)           (7,650)            
Net loss (63,312)                 (63,312)      
Issuance of common stock upon exercise of options (in shares)       470,843                  
Issuance of common stock upon exercise of options 746           746            
In-kind payment of preferred dividend (241,529)                 (241,529)      
Conversion of preferred stock into common stock (in shares)       153,895,644                  
Conversion of preferred stock into common stock 728,050     $ 15     728,035            
Recapitalization, net of transaction expenses (Note 3) (in shares)       28,898,374                  
Recapitalization, net of transaction expenses (Note 3) 236,973     $ 3     236,970            
Forward Purchase Agreement prepayment (60,547)           (60,547)            
Reclassification of warrants to equity 1,800           1,800            
Foreign currency translation (49)                     (49)  
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023       195,451,596                  
Ending balance at Mar. 31, 2023 $ 169,265     $ 19     927,641     (761,086)   2,691  
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022 129,148,393 29,521,810 99,626,583                    
Beginning balance, temporary equity at Dec. 31, 2022 $ 480,631 $ 480,631                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Exercise of a warrant, Series C and D Preferred Stock (in shares) 594,309                        
Exercise of a warrant, Series C and D Preferred Stock $ 5,890                        
In-kind payment of preferred dividend $ 241,529                        
Conversion of preferred stock into common stock (in shares) (129,742,702)                        
Conversion of preferred stock into common stock $ (728,050)                        
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023 0                        
Ending balance, temporary equity at Mar. 31, 2023 $ 0                        
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2023 196,642,451     196,642,451                  
Beginning balance at Dec. 31, 2023 $ 114,471     $ 19     943,960     (831,872)   2,364  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation expense 2,625           2,625            
Repurchase of equity instruments (48)           (48)            
Net loss $ (25,508)                 (25,508)      
Issuance of common stock upon exercise of options (in shares) 162,000     1,083,026                  
Issuance of common stock upon exercise of options $ 234           234            
Foreign currency translation $ 42                     42  
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2024 197,725,477     197,725,477                  
Ending balance at Mar. 31, 2024 $ 91,816     $ 19     $ 946,771     $ (857,380)   $ 2,406